Trials / Completed
CompletedNCT00224146
Transdermal (TDS) Oxybutynin (Oxytrol(r)) in Overactive Bladder
Multicenter Assessment of Transdermal Therapy in Overactive Bladder With Oxybutynin TDS (MATRIX)
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 2,878 (actual)
- Sponsor
- Watson Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study evaluates changes in health related quality of life outcomes in patients using Oxytrol(r)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | oxybutynin transdermal delivery system (Oxytrol(r)) |
Timeline
- Start date
- 2004-05-01
- Primary completion
- 2005-05-01
- Completion
- 2005-05-01
- First posted
- 2005-09-22
- Last updated
- 2011-11-30
Locations
10 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00224146. Inclusion in this directory is not an endorsement.